Clopidogrel Taw Pharma (previously Clopidogrel Mylan) Uni Eropa - Latvi - EMA (European Medicines Agency)

clopidogrel taw pharma (previously clopidogrel mylan)

taw pharma (ireland) limited - klopidogrela hidrohlorīds - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitrombotiskie līdzekļi - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

Rivastigmine 1 A Pharma Uni Eropa - Latvi - EMA (European Medicines Agency)

rivastigmine 1 a pharma

1 a pharma gmbh - rivastigmine - alzheimer disease; dementia; parkinson disease - psychoanaleptics, - simptomātiska vieglas vai vidēji smaga alcheimera demences ārstēšana. simptomātiska ārstēšana vieglas vai vidēji smagas demences pacientiem ar idiopātisko parkinsona slimība.

Bisacodyl Viatris 5 mg apvalkotās tabletes Latvia - Latvi - Zāļu valsts aģentūra

bisacodyl viatris 5 mg apvalkotās tabletes

viatris healthcare limited, ireland - bisakodils - apvalkotā tablete - 5 mg

Abacavir/Lamivudine Viatris 600 mg/300 mg apvalkotās tabletes Latvia - Latvi - Zāļu valsts aģentūra

abacavir/lamivudine viatris 600 mg/300 mg apvalkotās tabletes

viatris limited, ireland - abacavirum, lamivudinum - apvalkotā tablete - 600 mg/300 mg

Pemetrexed Viatris 25 mg/ml koncentrāts infūziju šķīduma pagatavošanai Latvia - Latvi - Zāļu valsts aģentūra

pemetrexed viatris 25 mg/ml koncentrāts infūziju šķīduma pagatavošanai

viatris limited, ireland - pemetrekseds - koncentrāts infūziju šķīduma pagatavošanai - 25 mg/ml

Tiotropium Viatris 18 mikrogrami inhalācijas pulveris, cietās kapsulas Latvia - Latvi - Zāļu valsts aģentūra

tiotropium viatris 18 mikrogrami inhalācijas pulveris, cietās kapsulas

viatris limited, ireland - tiotropijs - inhalācijas pulveris, cietā kapsula - 18 μg

Dutasteride/Tamsulosin Viatris 0,5 mg/0,4 mg cietās kapsulas Latvia - Latvi - Zāļu valsts aģentūra

dutasteride/tamsulosin viatris 0,5 mg/0,4 mg cietās kapsulas

viatris limited, ireland - dutasteridum, tamsulosini hydrochloridum - kapsula, cietā - 0,5 mg/0,4 mg

Dasatinib Viatris 50 mg apvalkotās tabletes Latvia - Latvi - Zāļu valsts aģentūra

dasatinib viatris 50 mg apvalkotās tabletes

viatris limited, ireland - dasatinibs - apvalkotā tablete - 50 mg

Ticagrelor Viatris 90 mg apvalkotās tabletes Latvia - Latvi - Zāļu valsts aģentūra

ticagrelor viatris 90 mg apvalkotās tabletes

viatris limited, ireland - ticagrelorum - apvalkotā tablete - 90 mg

Apixaban Viatris 2,5 mg apvalkotās tabletes Latvia - Latvi - Zāļu valsts aģentūra

apixaban viatris 2,5 mg apvalkotās tabletes

viatris limited, ireland - apiksabāns - apvalkotā tablete - 2,5 mg